Recent Updates on Chemotherapy-Induced Peripheral Neuropathy.
- Author:
In Sook WOO
1
Author Information
- Publication Type:Review
- Keywords: Chemotherapy; Peripheral neuropathy; Duloxetine
- MeSH: Alkaloids; Amitriptyline; Cisplatin; Drug Therapy; Extremities; Humans; Neural Conduction; Nortriptyline; Peripheral Nervous System; Peripheral Nervous System Diseases*; Platinum; Quality of Life; Bortezomib; Duloxetine Hydrochloride
- From:Korean Journal of Medicine 2015;88(1):35-37
- CountryRepublic of Korea
- Language:Korean
- Abstract: Chemotherapy induced peripheral neuropathy (CIPN) could debilitate the quality of life in the patients with cancer. According to the severity of CIPN, the modification of dosage of chemotherapeutic agents and switch to other drugs can be unavoidable. Platinum such as cisplatin and oxalipatin, vinka alkaloids, bortezomib, and taxane can cause CIPN. The characteristics and severity of CIPN depends on the dosages, duration of exposure of chemotherapeutic agents, comcomittant illness or other drugs affecting on peripheral nervous system and the methods of assessment for CIPN. The symptoms may last for several months or permanently even after quitting chemotherapy. Typically it distributed bilaterally and starts from the distal part of extremities and is presented progressively in stocking and glove pattern. Sensory nerve is more involved rather than motor nerve and amplitude of sensory nerve conduction is observed in CIPN. Prevention for CIPN is not effective at present. Tricyclic antidepressant including amitriptyline or nortriptyline and gabapentine have been tried in the practice for the management of CIPN despite of the lack of significant evidence through clinical trials. Recently duloxetine has been reported to decrease pain in the patients with CIPN compared with the patients with placebo (p = 0.03).
